This site provides INTERCEPT product information for Health Care Professionals in the United States.

Cerus Websites

Cerus Webinars

ASH 2021: Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study

Runtime: 5 min

“Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study”

Allison Wheeler, MD
Associate Medical Director, Blood Bank and Coagulation Laboratory – Vanderbilt University Medical Center

Dr. Allison Wheeler of Vanderbilt University Medical Center discusses results from the PIPER Phase 4 Study – the largest study of platelet transfusion associated pulmonary injury to-date with >10,000 platelet components transfused in >2,000 patients.

PIPER, or “Pathogen Inactivated Platelets Entering Routine Practice,” compares the pulmonary safety of conventional and pathogen reduced platelet components transfused to hematology-oncology patients.

View Dr. Wheeler’s presentation originally presented at the 63^rd ASH Annual Meeting, December 2021

View the abstract

INTERCEPT Blood System for Platelets and Plasma

WARNINGS AND CONTRAINDICATIONS

CONTRAINDICATIONS
Contraindicated for preparation of platelet or plasma components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of platelet or plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS
Only INTERCEPT Processing Sets for platelets or plasma are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet or plasma components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process.

Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

PLASMA
Amotosalen-treated plasma may cause the following adverse reaction: Cardiac Events

In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

Cerus.com

INTERCEPT-USA.com

HCP.INTERCEPT-USA.com

INTERCEPT-Canada.com

INTERCEPTBloodSystem.com

INTERCEPT-Cryoprecipitation.com

Cerus Webinars

ASH 2021: Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study

WARNINGS AND CONTRAINDICATIONS